How big is the Global Onychomycosis Treatment Market?

The Global Onychomycosis Treatment Market size is expected to reach USD 3.36 billion in 2024 and grow at a CAGR of 4.46% to reach USD 4.18 billion by 2029. Read More

What is the current Global Onychomycosis Treatment Market size?

In 2024, the Global Onychomycosis Treatment Market size is expected to reach USD 3.36 billion. Read More

Who are the key players in Global Onychomycosis Treatment Market?

Bausch Health Companies Inc (Valeant Pharmaceuticals Inc) , Galderma S.A., Novartis AG, Pfizer, Inc and Moberg Pharma AB are the major companies operating in the Global Onychomycosis Treatment Market. Read More

Which is the fastest growing region in Global Onychomycosis Treatment Market?

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Global Onychomycosis Treatment Market?

In 2024, the North America accounts for the largest market share in Global Onychomycosis Treatment Market. Read More

What years does this Global Onychomycosis Treatment Market cover, and what was the market size in 2023?

In 2023, the Global Onychomycosis Treatment Market size was estimated at USD 3.22 billion. The report covers the Global Onychomycosis Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Onychomycosis Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Global Onychomycosis Treatment Market Share

Statistics for the 2023 & 2024 Global Onychomycosis Treatment market share, created by Mordor Intelligence™ Industry Reports. Global Onychomycosis Treatment share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Market Share of Global Onychomycosis Treatment Industry

The onychomycosis treatment market is fragmented and competitive and consists of several major players. Companies are focusing on developments, collaborations, and product launches to strengthen their market position. For instance, in April 2020, the US Food and Drug Administration expanded the approval of Jublia manufactured by Bausch Health. Jublia is a topical solution used to treat onychomycosis in the toenail(s) in patients aged six years and above.

Some of the players currently dominating the market are Bausch Health Companies Inc. (Valeant Pharmaceuticals Inc.), Galderma SA, Novartis AG, Pfizer Inc., Moberg Pharma AB, Johnson & Johnson, Bayer AG, Dr. Reddy's Laboratories Ltd, Cipla Ltd, Medimetriks Pharmaceuticals Inc., and Lumenis Ltd.